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DRAM-3 modulates autophagy and promotes cell
survival in the absence of glucose
M Mrschtik1, J O’Prey1, LY Lao1, JS Long1, F Beaumatin1, D Strachan1, M O’Prey1, J Skommer1 and KM Ryan*1
Macroautophagy is a membrane-trafficking process that delivers cytoplasmic constituents to lysosomes for degradation. The
process operates under basal conditions as a mechanism to turnover damaged or misfolded proteins and organelles. As a result, it
has a major role in preserving cellular integrity and viability. In addition to this basal function, macroautophagy can also be
modulated in response to various forms of cellular stress, and the rate and cargoes of macroautophagy can be tailored to facilitate
appropriate cellular responses in particular situations. The macroautophagy machinery is regulated by a group of evolutionarily
conserved autophagy-related (ATG) proteins and by several other autophagy regulators, which either have tissue-restricted
expression or operate in specific contexts. We report here the characterization of a novel autophagy regulator that we have termed
DRAM-3 due to its significant homology to damage-regulated autophagy modulator (DRAM-1). DRAM-3 is expressed in a broad
spectrum of normal tissues and tumor cells, but different from DRAM-1, DRAM-3 is not induced by p53 or DNA-damaging agents.
Immunofluorescence studies revealed that DRAM-3 localizes to lysosomes/autolysosomes, endosomes and the plasma
membrane, but not the endoplasmic reticulum, phagophores, autophagosomes or Golgi, indicating significant overlap with
DRAM-1 localization and with organelles associated with macroautophagy. In this regard, we further proceed to show that DRAM-3
expression causes accumulation of autophagosomes under basal conditions and enhances autophagic flux. Reciprocally,
CRISPR/Cas9-mediated disruption of DRAM-3 impairs autophagic flux confirming that DRAM-3 is a modulator of macroautophagy.
As macroautophagy can be cytoprotective under starvation conditions, we also tested whether DRAM-3 could promote survival on
nutrient deprivation. This revealed that DRAM-3 can repress cell death and promote long-term clonogenic survival of cells grown in
the absence of glucose. Interestingly, however, this effect is macroautophagy-independent. In summary, these findings constitute
the primary characterization of DRAM-3 as a modulator of both macroautophagy and cell survival under starvation conditions.
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Macroautophagy (hereafter autophagy) is a cellular process
that delivers cytoplasmic constituents to lysosomes for
degradation.1 Autophagy operates at basal levels in virtually
all, if not all, cells. At the initiation of autophagy, membranes
termed isolation membranes nucleate in the cytoplasm from a
variety of sources.2–5 Two ubiquitin-like conjugation mechan-
isms involving evolutionarily conserved autophagy-related
(Atg) genes then function together to expand these mem-
branes to form the characteristic organelles of autophagy, the
autophagosome.6,7 During this process, cargoes are recruited
to the lumen of the autophagosome via a protein called LC3,
which becomes tethered to autophagosome membranes
during biogenesis.8 Adapter proteins such as p62/SQSTM1,
NBR1 andOPTN then act as ‘bridges’ for cargo recruitment by
simultaneously binding LC3, and the ubiquitin moieties on
proteins and organelles destined for degradation.9
Following autophagosome formation, a variety of fusion
events can occur with other organelles including multi-
vesicular bodies and endosomes.10 Ultimately, however,
fusion occurs with lysosomes to form new organelles called
autolysosomes in which lysosomal acidic hydrolases invoke
cargo degradation.10,11 Under basal conditions, the break-
down products are then recycled into biosynthetic path-
ways.10,11 As a result, autophagy is a critical mechanism
within cells to remove damaged proteins and organelles,
thereby preserving cellular fidelity, homeostasis and ultimately
viability of the cell and organism.1,12
Autophagy can also be modulated by a variety of internal
and external cues.13 This can increase the rate of autophagic
flux and/or modulate the cargoes that are digested. In this
regard, several selective forms of autophagy have been
described including mitophagy – the selective digestion
of mitochondria.14,15 The best characterized situation in
which autophagy is modulated is in response to starva-
tion conditions.16–19 This evolutionarily conserved response
utilizes autophagy to provide fuel for catabolic pathways to
maintain ATP levels during periods of diminished nutrient
availability.
1Tumour Cell Death Laboratory, Cancer Research UK Beatson Institute, Garscube Estate, Switchback Rd, Glasgow G61 1BD, UK
*Corresponding author: KM Ryan, Tumour Cell Death Laboratory, Cancer Research UK Beatson Institute, Garscube Estate, Switchback Road, Glasgow G61 1BD, UK.
Tel: +44 141 330 3655; Fax: +44 141 942 6521; E-mail: k.ryan@beatson.gla.ac.uk
Received 11.7.14; revised 15.2.15; accepted 16.2.15; Edited by G Kroemer; published online 01.5.15
Abbreviations: DRAM-1, damage-regulated autophagy modulator 1; DRAM-2, damage-regulated autophagy modulator 2; DRAM-3, DRAM-related/associated
member 3; Atg, autophagy-related; LC3, microtubule-associated protein 1A/1B-light chain 3; p62/SQSTM1, sequestosome 1; NBR1, neighbor of BRCA1 gene 1; OPTN,
optineurin; LAMP2, lysosome-associated membrane protein 2; EEA1, early endosome antigen 1; TNFα, tumor necrosis factor; IFN-γ, interferon-gamma; COX IV,
cyctochrome c oxidase subunit IV; XIAP, X-linked inhibitor of apoptosis; CCCP, carbonyl cyanide m-chlorophenyl hydrazone; Crispr, clustered regularly interspaced short
palindromic repeats; Cas9, Crispr-associated protein 9; PI, propidium iodide; GFP, green fluorescent protein; YFP, yellow fluorescent protein
Cell Death and Differentiation (2015) 22, 1714–1726
& 2015 Macmillan Publishers Limited All rights reserved 1350-9047/15
www.nature.com/cdd
Figure 1 DRAM-3 is expressed in various human tissues and cancer cell lines. (a) Alignment of DRAM-3 and DRAM-1. DRAM-3 shares 30% identity and 43% similarity with
DRAM-1 at the amino-acid level. (b) Schematic representation of DRAM-3. DRAM-3 is predicted to encode for a 233-aa protein with six putative transmembrane domains and a
predicted N-terminal signal peptide. (c) DRAM-3 mRNA expression varies in different body tissues. qRT-PCR products of the Origene TissueScan Human Normal cDNA Array
using Origene primers against DRAM-3 on a 2% agarose gel. (d) Quantification of qRT-PCR from (c). GAPDH was used as a standard. (e) DRAM-3 mRNA expression in a panel
of cancer cell lines. Results obtained through qRT-PCR. All values were measured in triplicates and normalized to 18S RNA. The red line denotes the detection limit of the qRT-
PCR. (f) DRAM-1 mRNA expression in a panel of cancer cell lines. Results obtained through qRT-PCR. All values were measured in triplicates and normalized to 18S RNA. All
values shown were above the detection limit
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Figure 2 Regulation of DRAM-3 expression in selected cancer cell lines. (a) Western blot of Saos-2 tet-on p53 cells with and without addition of doxycycline. p53 is induced
by doxycycline in a time-dependent manner. (b) DRAM-3 is not induced by p53. In Saos-2 tet-on p53 cells, DRAM-3 mRNA is not induced after addition of doxycyline, while
DRAM-1 mRNA is upregulated. Results obtained through qRT-PCR. The data represented are from three independent experiments and are plotted as means; error bars are S.E.
M. (c, d) Analysis of DRAM-3 mRNA levels in response to various stimuli in p53-null Saos-2 cells (c) or p53 wild-type U2OS cells (d). Results obtained through qRT-PCR. Values
shown are relative to control, which was normalized to 1. The data represented are from three independent experiments and are plotted as means; error bars are S.E.M. (e, f)
Analysis of DRAM-1 mRNA levels in response to various stimuli in p53-null Saos-2 cells (e) and p53 wild-type U2OS cells (f). Results obtained through qRT-PCR. Values shown
are relative to control, which was normalized to 1. The data represented are from three independent experiments and are plotted as means; error bars are S.E.M. (c–f) No glucose
medium contained 10% dialyzed FBS
DRAM-3 promotes autophagy and cell survival
M Mrschtik et al
1716
Cell Death and Differentiation
To understand the regulation of autophagy, it is important to
identify factors that regulate the process in both general and
specific situations. For example, we previously identified
DRAM-1 (damage-regulated autophagy modulator-1) as an
autophagy regulator downstream of the tumor suppressor
p53.20,21 Subsequently, we found that DRAM-1 belongs to a
previously undescribed, evolutionarily-conserved protein
family.22 To date, however, we have only characterized
DRAM-1 and the most related protein in terms of amino-acid
sequence that we termed DRAM-2.22 We report here initial
characterization of another DRAM-1-related protein that is
encoded by TMEM150B and that we have named DRAM-3.
This protein localizes to endosomes and autolysosomes/
lysosomes, but unlike DRAM-1 is not induced by p53.
DRAM-3 does, however, regulate autophagic flux and pro-
motes cell survival in response to nutrient deprivation, but
DRAM-3’s effect on cell survival is autophagy-independent.
Results
DRAM-3 is expressed in multiple tissues and tumor cell
lines, but is not induced by a variety of stimuli. To identify
DRAM-1-related proteins we performed Blast searches using
the DRAM-1 peptide sequence. One protein identified
comprises 233 amino acids and has 30% identity and 43%
similarity to DRAM-1 (Figure 1a). This protein is encoded by
TMEM150B, but, due to its homology to DRAM-1, we decided
to rename this gene and its protein product, DRAM-3 (DRAM-
Related/Associated Member 3). Analysis of the DRAM-3
peptide sequence revealed that, like DRAM-1,20,23 DRAM-3
appears to contain a signal peptide and several hydrophobic
regions, indicating that DRAM-3 is likely a transmembrane
protein located in one or more compartments of the secretory
pathway (Figure 1b).
We next analyzed DRAM-3 expression in a variety of human
tissues that revealed DRAM-3 is clearly detectable in some,
but not all tissues (Figure 1c). Quantification revealed that the
colon and lung had the highest DRAM-3 mRNA levels with
comparatively high levels also detectable in the lymph nodes,
placenta, duodenum, peripheral blood mononuclear cells and
spleen. Other tissues either had very little or undetectable
levels of DRAM-3 mRNA (Figure 1d). We also profiled
DRAM-3 expression in human tumor cell lines, which again
showed expression in some lines, but virtually no expression
in others (Figure 1e). DRAM-1 was also selectively expressed,
but there did not appear to be any level of co-regulation of the
two genes across the lines (Figure 1f).
Our previous studies showed DRAM-1 is markedly induced
by p53.20 By contrast, DRAM-2 is not induced in this context.22
We were therefore keen to examine whether DRAM-3 was
modulated by p53. We utilized a previously described Saos-2
cell line (null for endogenous p53), which contains a tetracycline-
responsive p53 transgene.24 Treatment of these cells with
doxycycline (Dox) potently upregulates p53 with maximal
expression being reached by 24 h (Figure 2a). DRAM-1 mRNA
was also induced over this time frame (Figure 2b),20 but
DRAM-3, like DRAM-2, was completely unaffected (Figure 2b).
Although unaffected by p53, we considered that DRAM-3
expression may be modulated by factors that elicit an
autophagic or cellular stress response. We therefore treated
U2OS, HepG2, A549 and LNCaP cells (wild-type for endo-
genous p53) and Saos-2 and H1299 cells (p53-null) with,
where indicated, cisplatin, etoposide, actinomycin D, TNFα
and IFN-γ. Saos-2 and U2OS cells were also incubated in
either Earle’s Balanced Salt Solution (EBSS, a medium
lacking amino acids and serum) or regular medium lacking
serum or glucose. DNA-damaging agents have been reported
to upregulate DRAM-1 in cells containing wild-type p53,20
but no induction of DRAM-3 was observed in response to
etoposide, actinomycin D or cisplatin in any of the cells tested
whether wild type or null for p53 (Figure 2c and d and
Supplementary Figure 1). Similarly, DRAM-3 was not induced
in response to TNFα or IFN-γ, nor was any effect observed on
incubation in starvation conditions (Figure 2c and d). The
effect of these treatments on DRAM-1 mRNA levels is shown
for comparison (Figure 2e and f). We conclude that DRAM-3
levels vary widely between different tissues, but, at least in the
cells tested, DRAM-3 is not markedly up- or downregulated by
DNA damage, nutrient deprivation or by exposure to TNFα and
IFN-γ.
DRAM-3 localizes to various compartments within the
cell. DRAM-1 and DRAM-2 localize to lysosomes.20,22 In
addition, DRAM-1 is also found in early endosomes, late
endosomes and autophagosomes with smaller isoforms of
DRAM-1 showing partial localization in the peroxisomes and
ER.25 We therefore tested whether DRAM-3 occupies similar
or different subcellular compartments when compared with
DRAM-1 and DRAM-2. This revealed that DRAM-3, like
DRAM-1, was detectable in regions of the cell stained with
antibodies against LAMP2, LC3B (punctate stain) and the
endosomal marker, EEA1 (Figure 3a–c). In addition and in
contrast to DRAM -1 and DRAM-2, DRAM-3 was also found
in the plasma membrane with a concentrated localization at
actin-rich focal adhesions (Figure 3d). Localization in the
plasma membrane and endosomes was also confirmed by
live-cell imaging (Figure 3e and f). By contrast, DRAM-3 was
not found in phagophores, the endoplasmic reticulum or Golgi
(Figure 3g and h and Supplementary Figure 2a).
Because LC3B is connected to autophagy, we explored
the relationship between DRAM-3 and LC3B more closely.
Quantification of LC3B colocalized with DRAM-3 revealed
that ~ 20% of LC3B is in close proximity to DRAM-3
(Supplementary Figure 2b). By contrast, o5% of DRAM-3
can be found in close proximity to LC3B (Supplementary
Figure 2b). In addition, because LC3B marks both autophago-
somes and autolysosomes, we examined the localization of
DRAM-3-associated LC3B. Interestingly, cellular regions that
stain positive for DRAM-3 and LC3B also appear positive for
LAMP2 (Supplementary Figure 2c), indicating that when
DRAM-3 associates with LC3B it does so in autolysosomes.
Taken together, these findings identify common and also
divergent localization sites for DRAM-3 when compared with
DRAM-1 and DRAM-2.
DRAM-3 promotes autophagy, but does not affect cell
viability in replete nutrient conditions. DRAM-1 can con-
tribute to p53’s cell death response,20 but when expressed
alone it has no detrimental impact on cell viability.20 To test
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whether DRAM-3 affects cell death, we generated tetra-
cycline-regulated DRAM-3-inducible cells. In these cells, a
small, but reproducible increase in cells with sub-G1 DNA
was observed 48 h after DRAM-3 induction (Figure 4a), but
this effect was not statistically significant (Figure 4a). In line
with a lack of apoptosis, DRAM-3 expression does not induce
any detectable increase in the cleaved form of caspase 3
(Supplementary Figure 3a). Annexin V/Propidium iodide (PI)
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staining also showed that DRAM-3 has no impact on
apoptosis (Annexin V-positive, PI-negative cells), although a
small increase in cells that were Annexin V positive and PI
positive indicates that DRAM-3 may cause a small amount of
necrosis (Supplementary Figure 3b).
It was difficult to know whether DRAM-3 expression has a
long-term effect on cell viability using this system because
DRAM-3 expression becomes attenuated over time
(Figure 4b). Induction of DRAM-3 in two waves (1 week of
Dox, followed by 1 week without Dox and then addition of
Dox again) resulted in lower DRAM-3 levels at the second
round of induction, indicating potentially that some DRAM-3-
expressing cells (possibly those with the highest DRAM-3
levels) had died during the first wave of induction
(Supplementary Figure 3c).
To test the long-term effects of DRAM-3 on cell death, we
infected Saos-2 cells with a retrovirus expressing Myc-tagged
DRAM-3 or an ‘empty’ retroviral construct as a control (Figure
4c and d). This revealed that retroviral expression of DRAM-3
had no impact on cell growth in the short-term nor did it affect
the clonogenic potential of cells in the long term (Figure 4e and
f). Therefore, whereas high levels of DRAM-3 may affect cell
viability, lower levels do not affect growth or viability when
expressed alone in replete medium.
The best characterized effect of DRAM-1 is on autophagy20
and so we tested whether DRAM-3 is also an autophagy
modulator. First, we analyzed LC3B distribution in cells
expressing DRAM-3. In cells with low levels of autophagy,
the majority of LC3B is diffused in the cytoplasm in a form
termed LC3-I. On autophagosome formation, LC3-I is cleaved
and becomes conjugated to phosphatidylethanolamine to give
the form of LC3 termed LC3-II. In this form, LC3B integrates
into the autophagosome membrane via its lipid moiety.8 As a
result, the appearance of LC3B puncta by immunofluores-
cence can be used as a measure of autophagosome levels
and an indicator of changes in autophagic flux. In replete
growth medium, DRAM-3-expressing cells had significantly
more LC3B-positive puncta than control cells (Figure 5a and
b). Western blotting for LC3-II also showed increased levels of
LC3-II in DRAM-3-expressing cells when compared with
controls (Figure 5c and Supplementary Figure 4a–c). Under
starvation conditions, however, where autophagy is markedly
induced, the difference between DRAM-3-expressing and
control cells was no longer apparent (Figure 5a–c).
Increased LC3B puncta or LC3-II levels can indicate
enhanced autophagic flux, but, as most cells have a basal
autophagic rate, an increase can also indicate a block or
retardation in autophagosome turnover. To discern between
these two possibilities, we examined LC3B accumulation
following treatment with the lysosomotropic agent,
chloroquine, to block autophagosome turnover. Cells with
higher rates of flux accumulate more LC3-II upon chloroquine
treatment than those with lower flux. However, if cells already
have blocked flux, treatment with chloroquine causes no
further increase in the levels of LC3-II. In the context of
DRAM-3 expression, we found that chloroquine caused a
greater accumulation of LC3-II when compared with control
(Figure 5d), indicating that DRAM-3 promotes autophagic flux.
Interestingly, the autophagy adaptor protein p62/SQSTM1,
which is often used as a measure of flux,26 was not increased
by chloroquine treatment (Figure 5d), nor was it affected
by incubation in EBSS (Figure 5c). This indicates that,
although useful in some scenarios, p62/SQSTM1 is not
actively degraded by autophagy in these cells under these
conditions and therefore cannot be utilized to measure
autophagic flux.
To address this issue further we analyzed autophagic flux by
‘enhanced-mitophagy’.27 To do this, we infected DRAM-3-
expressing and control cells with a retrovirus-expressing
Parkin. Treatment of Parkin-expressing cells with the mito-
chondrial uncoupling agent CCCP causes autophagy-
dependent loss of mitochondria, with the rate of loss being
dependent on the autophagic capacity and rate in the cell.
Using this system we found that depletion of the mitochondrial
protein COX IV was greater in DRAM-3-expressing cells when
compared with controls (Figure 5e), confirming that DRAM-3
promotes autophagic flux.
We next tested whether DRAM-3 affects autophagy in
another line. As Saos-2 have relatively high DRAM-3 levels,
we decided to examine MDA-MB-231 cells in which endo-
genous DRAM-3 levels are comparatively low (Figure 1e). In
contrast to Saos-2 cells, DRAM-3 expression in MDA-MB-231
did not affect basal LC3-II levels, indicating that this effect may
be cell-type specific (Figure 5f). On starvation, however, there
was less LC3-I and LC3-II in DRAM-3-expressing cells
(Figure 5f), indicating that DRAM-3 was promoting autophagic
flux. To examine this further, we treated with chloroquine,
which caused a greater accumulation of LC3-II in DRAM-3-
expressing MDA-MB-231 cells when compared with controls
(Figure 5g), showing in line with what was observed in
Saos-2 (Figure 5d and e) that DRAM-3 promotes
autophagic flux.
As DRAM-3 overexpression enhances autophagic flux, we
were keen to ascertain whether loss of endogenous DRAM-3
could also affect autophagic flux. To do this we utilized
CRISPR/Cas9 technology to introduce mutations in the dram-
3 gene, which disrupt DRAM-3 expression. In the absence of
an effective DRAM-3 antibody, we performed two tests to
confirm CRISPR/Cas9 targeting of the dram-3 locus. First, we
sequenced DNA from DRAM-3-targeted cells in the region
Figure 3 DRAM-3 localizes to a variety of cellular compartments (a–d). Exogenous DRAM-3 partially localizes within close proximity to the autophagosome marker LC3B (a),
the early endosome marker EEA1 (b), the lysosome marker LAMP2 (c) and actin-coated pits (d). Actin staining was performed using Phalloidin-red. DRAM-3 was visualized with
an α-Myc-Tag antibody. Immunofluorescence analysis was performed on a Zeiss 710 confocal microscope with × 63 objective. (e) DRAM-3 containing vesicles closely localize to
Rab5-containing vesicles in live cells. GFP-tagged DRAM-3 and RFP-tagged early endosome marker Rab5 were co-transfected into Saos-2 cells via calcium phosphate
transfection. Live-cell imaging was performed after a minimum of 2 days on an Andor spinning disc confocal system. (f) DRAM-3 containing vesicles partially localize close to
Rab7-containing vesicles in live cells. GFP-tagged DRAM-3 and RFP-tagged late endosome marker Rab7 were co-transfected into Saos-2 cells via calcium phosphate
transfection. Live-cell imaging was performed after a minimum of 2 days on an Andor spinning disc confocal system. (g) Exogenous DRAM-3 does not colocalize with Golgi
marker GM130. Immunofluorescence analysis was performed on an Olympus FV1000 confocal microscope with × 60 objective. (h) Exogenous DRAM-3 does not colocalize with
endoplasmic reticulum marker Calnexin. Immunofluorescence analysis was performed on an Olympus FV1000 confocal microscope with × 60 objective
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targeted by the CRISPR guide RNA. This revealed major
disruption of dram-3 DNA sequence in cells targeted with a
DRAM-3 guide RNA when compared with those targeted with
a GFP guide RNA (Figure 6a). To test whether the DRAM-3
CRISPR/Cas9 could also disrupt protein expression, we
transfected the two cell pools with a plasmid expressing
DRAM-3-GFP. Expression of DRAM-3-GFP was clearly
detectable in control cells, but expression was lost in cells
expressing guide RNAs targeting DRAM-3 or GFP, indicating
effective targeting of dram-3 and gfp sequences in these two
cell pools (Figure 6b).
In contrast to DRAM-3-overexpressing cells, there was no
difference in basal LC3-II levels between wild type and
DRAM-3-knockout cells (Figure 6c). However, incubating cells
in chloroquine, as outlined above and as previously
described,26 caused greater LC3-II accumulation in control
cells (GFP) than in cells with DRAM-3 disruption (Figure 6d
and Supplementary Figure 4d–f). This is reciprocal to what
was observed on retroviral overexpression of DRAM-3 and
confirms that DRAM-3 is a modulator of autophagic flux.
Interestingly, although this result was seen in several
independent experiments, in some cases no effect was
Figure 4 DRAM-3 does not affect apoptotic cell death or cell growth processes. (a) DRAM-3 overexpression does not induce apoptotic cell death. Saos-2 Tet-On DRAM-3
cells were treated with doxycycline for 48 h and analyzed for Sub-G1 content via FACS (a reliable measure of apoptotic death). The data represented are from three independent
experiments and are plotted as means. Error bars represent S.E.M. Statistical analysis was undertaken with an unpaired t-test. (b) DRAM-3 expression is strongly induced after
doxycycline treatment of Saos-2 Tet-On DRAM-3 cells. Cells were induced with doxycycline for 24, 48 and 72 h, and western blot analysis was performed to ensure DRAM-3
expression. The doxycycline-inducible construct is fused to a Myc-His tag, and an α-Myc-tag antibody was used to detect the exogenous protein. (c) Cells stably overexpressing
DRAM-3-Myc-His were generated via ecotropic viral infection of Saos-2 EcoR cells. The extent of DRAM-3 overexpression was measured in triplicates by qRT-PCR, and DRAM-3
measurements were normalized to 18S RNA. Data represent means. Error bars are S.D. (d) Saos-2 pWZL DRAM-3 cells express DRAM-3 protein. DRAM-3 protein was
visualized via western blot, using an α-Myc-tag antibody. (e) Saos-2 cells stably overexpressing DRAM-3 do not show proliferation defects. DRAM-3 overexpressing and control
cells were counted in triplicates on the specified days, and a growth curve was generated for the course of 6 days. (f) Infection of Saos-2 cells with a retroviral construct (pWZL)
expressing DRAM-3 does not impair clonogenic survival under standard growth conditions. Saos-2 pWZL and pWZL DRAM-3 cells were seeded at low density 1 week after
selection
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observed. This indicates perhaps that DRAM-3 has a role that
is dependent on the cellular nutrient status as would be the
case for the majority of autophagic responses.
To test whether DRAM-3 loss has an effect on autophagy by
affecting the number or localization of structures associated
with autophagy – phagophores, autophagosomes and auto-
lysosomes/lysosomes – we stained wild type (Crispr GFP) and
DRAM-3 Crispr cells with antibodies against WIPI2, LC3B and
LAMP2. No differences, however, were seen between the two
cell lines (Figure 6e). In addition, because the endocytic
pathway can affect autophagic flux, we also examined
endosomes, but staining for EEA1 looked similar in wild type
and DRAM-3-expressing cells (Supplementary Figure 5a). This
doesnot, however, provide proof that endocytosis is not affected
and so we examined uptake of bovine serum albumin (BSA)
over time, but again no difference was evident between wild-
type and DRAM-3-expressing cells (Supplementary Figure 5b
and c). Collectively, this shows DRAM-3 does not affect
endocytosis and that differences in endosomes or endocytic
rate cannot explain the effects of DRAM-3 on autophagy.
DRAM-3 promotes autophagy-independent survival on
glucose deprivation. As we found DRAM-3 is a regulator of
autophagic flux, we re-visited the possibility that DRAM-3
may affect cell viability, but this time under starvation
conditions where autophagy can be critical for cell
survival.16–19 This indeed revealed that DRAM-3-expressing
Saos-2 and MDA-MB-231 cells had enhanced clonogenic
potential when grown in low serum without glucose (Figure
7a and b and Supplementary Figure 6a). This effect
appeared cell death-related, as a difference in propidium
iodide exclusion (a measure of cell membrane permeability
and by association, cell death) was also observed between
DRAM-3-expressing and control cells (Figure 7c). By
contrast, no major differences in cell-cycle stage or sub-G1
DNA content (a measure of apoptotic cell death) were evident
in either replete medium or starvation conditions (Figure 7d).
Further analysis again showed DRAM-3’s effect on cell death
was not apoptotic, as the extent of death was not significantly
affected by treatment with the pan-caspase inhibitor zVAD-
fmk (Supplementary Figure 6b). Interestingly, we also noted
that this difference in cell survival may not be related to the
ability to supply energy in the absence of glucose, as the
difference was also evident when cells were incubated in
pyruvate, an alternative source of fuel (Figure 7e). Analysis of
cells under these conditions by Annexin V/PI staining again
showed that the difference in cell death was not apoptotic
(Annexin V-positive, PI-negative) and was more likely down to
differences in necrosis (Annexin V-positive, PI-positive)
(Supplementary Figure 6c).
We also tested whether DRAM-3 loss would decrease
survival under glucose-deprived conditions. This revealed,
however, that loss of DRAM-3 had no impact on cell viability
(Supplementary Figure 6d). A result of this kind, however, is
not without precedent. For example, XIAP overexpression
represses death in multiple situations and yet XIAP-deficient
mice are perfectly viable,28 indicating that XIAP loss does not
lead to excessive cell death in these animals. It may be that the
cells adapt to DRAM-3 loss to survive and/or we have not yet
found a condition where endogenous DRAM-3 is critical.
Alternatively, because DRAM-3 belongs to a family of proteins,
another DRAM protein may compensate for DRAM-3 loss in
this scenario.
Finally, we examined whether the differences we had
observed in cell death under starvation conditions
were related to DRAM-3’s effects on autophagy. LC3-II
accumulated in both DRAM-3-expressing and control cells
when incubated in low serum without glucose (Figure 7f and
Supplementary Figure 7), and to test whether this was
biologically significant, we repeated PI exclusion assays as
described in Figure 7c, but this time in the presence of
chloroquine. If autophagy was responsible for the increased
survival of DRAM-3-expressing cells, this should be elimi-
nated by chloroquine. We found, however, that DRAM-3’s
ability to repress cell death in low serum with no glucose was
unaffected by treatment with chloroquine, indicating that
DRAM-3 mediates this effect in an autophagy-independent
manner (Figure 7g). This effect was confirmed by analysis of
Annexin V/PI staining (Supplementary Figure 6e).
Discussion
We describe here the primary characterization of DRAM-3, a
new regulator of autophagy. DRAM-3 shares significant
sequence homology with DRAM-1 and localizes to some
similar subcellular compartments. Different from DRAM-1,
however, DRAM-3 is not induced by p53 or DNA damage.
DRAM-3 is also not induced by other autophagy-associated
stimuli including culture in EBSS, low glucose, low serum or by
treatment with IFN-γ or TNF.17–19,29,30 It remains possible that
DRAM-3 could be induced by other DRAM-1-inducing stimuli,
for example, the p53 family member, p73.31 Equally, dram-3
may be a gene that is not overtly modulated and yet its function
is still important for basal autophagy. In this regard, it is notable
that DRAM-3 is readily detectable in multiple tissues and cells,
whereas DRAM-1 is virtually undetectable in many tissues in
the absence of DNA-damage. Interestingly, we have also
examined the levels of dram-3 gene dosage using the
cBioPortal database, which revealed that dram-3 is frequently
amplified in various tumor types (Supplementary Figure 8).
We have no evidence, however, that dram-3 is the driving force
for gene amplification in this region and this may instead be
connected to a nearby gene to which dram-3 is linked.
As outlined above, one parallel between DRAM-1 and
DRAM-3 is subcellular localization. Both proteins localize
to endosomes, autolysosomes and lysosomes, and it is
plausible that the two proteins perform similar or linked functions
at these locations. However, the question remains whether they
regulate autophagy in a redundant or in a concerted manner
when DRAM-1 is induced by DNA damage, and further studies
in this area are undoubtedly worthwhile.
Perhaps the most surprising finding from our study was the
fact that while DRAM-3 can positively modulate autophagy, its
ability to promote survival under starvation conditions is
autophagy-independent. This function of DRAM-3 may be
associated with its localization to the plasma membrane, a
region not currently considered to be involved in autophagy
beyond its participation as a source of membrane for
autophagosome biogenesis.4 DRAM-3 may have some role
in extracellular matrix engulfment or growth factor receptor
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recycling, both of which can modulate cell survival. Interest-
ingly, DRAM-3’s localization at the plasma membrane is not
uniform with particularly focused localization at focal adhe-
sions. As focal adhesions can also signal cell survival via
integrins,32 this may also be an area of focus for subsequent
studies on DRAM-3 function.
In summary, to the best of our knowledge, this is the first
study detailing DRAM-3 as a modulator of autophagy and,
independently, cell survival under starvation conditions.
Although many questions remain regarding the function of
DRAM-3, due to the intense current interest in autophagy,
nutrient sensing and cellular adaptation to starvation condi-
tions, we hope that the findings we present here act as a
starting point and catalyst for further investigation into the
mechanism of action and functional consequences of this
interesting new protein.
Figure 5 DRAM-3 overexpression affects autophagic processes. (a) The levels of LC3B puncta are increased in cells stably overexpressing DRAM-3. Saos-2 cells were
treated with control or starvation media (EBSS) for 2 h and examined by immunofluorescence analysis. Endogenous autophagosomes were visualized with LC3B-specific
antibody on a Zeiss 710 confocal microscope with × 63 objective. (b) Quantification of (a). Immunofluorescence stacks were overlayed with maximum intensity, and the area of
LC3B puncta relative to the cell area was measured using Image J. Quantification of 12 cells per condition. A Student’s t-test was performed as statistical analysis, and the bars in
the figure represent mean values; errors are S.D. NSP40.05; **Po0.01. (c) DRAM-3 overexpression increases LC3-II levels under normal growth conditions. Saos-2 cells stably
overexpressing DRAM-3 were subjected to 1 or 2 h EBSS starvation or DMEM supplemented with 10% FBS and Glutamine. (d) DRAM-3 overexpression increases autophagic
flux. Saos-2 cells stably overexpressing DRAM-3 were subjected to 5 μM chloroquine treatment (CQ) for 2 h. (e) DRAM-3 overexpression accelerates mitophagy. Saos-2 Eco
cells containing DRAM-3 or control (pWZL) constructs and overexpressing Parkin-YFP were treated with 12.5 μM CCCP two times during a 24 h period and then analyzed for
quantity of mitochondria via western blotting, using an α-COX IV antibody. (f) DRAM-3 overexpression modulates autophagic flux in different cell lines. MDA-MB-231 cells stably
overexpressing DRAM-3 were subjected to 1 or 2 h EBSS starvation or DMEM supplemented with 10% FBS and glutamine. (g) DRAM-3 overexpression increases autophagic
flux in different cell lines. MDA-MB-231 cells stably overexpressing DRAM-3 were subjected to 5 μM chloroquine treatement (CQ) for 2 h
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Materials and Methods
Cell culture, transfections and infections. All cells (except for HL-60,
Raji and Jurkat cell lines) were grown in DMEM high glucose supplemented with
10% FBS, 0.292 mg/ml Glutamine and Penicillin (100 Units/ml)/Streptomycin
(100 μg/ml) (all from Life Technologies, Carlsbad, CA, USA). Suspension cells
(HL-60, Raji and Jurkat) were grown in RPMI (Life Technologies) supplemented with
the reagents mentioned above.
For starvations, EBSS (Sigma, St. Louis, MO, USA) or DMEM no glucose (Gibco,
Life Technologies) supplemented with 2% or 10% dialyzed FBS (Gibco) and sodium
pyruvate (Life Technologies), as indicated, were used. Where indicated, late-stage
Figure 6 dram-3 disruption does not affect the number or localization of phagophores, autophagosomes and lysosomes. (a) lentiCRISPR disruption of DRAM-3 in Saos-2
cells. Genomic DNA from Saos-2 cells infected with lentivirus containing control (GFP) or DRAM-3-targeting constructs was sequenced for CRISPR-induced DNA frameshifts. (b)
lentiCRISPR cells efficiently inactivate expression of exogenous DRAM-3-GFP. Saos-2 cells containing lentiCRISPR contructs targeting GFP or DRAM-3 were transfected with
10 μg DRAM-3-GFP plasmid and collected 2 days after transfection for western blot analysis. (c) Analysis of autophagic responses on starvation in DRAM-3-knockout cells.
Saos-2 DRAM-3 disrupted and control cells were subjected to EBSS starvation for 1–2 h. (d) Autophagic flux is reduced on DRAM-3 disruption. Saos-2 DRAM-3 disrupted and
control cells were subjected to +/− addition of 5 μM chloroquine (an inhibitor of autophagic flux). (e) The appearance of cell structures associated with autophagy (phagophores,
autophagosomes and autolysosomes/lysosomes) do not change on DRAM-3 disruption. Saos-2 DRAM-3 disrupted and control cells were grown on coverslips and stained for
immunofluorescence analysis with LC3B together with WIPI2 or LAMP2 antibodies. Imaging was performed on a Zeiss LSM710 microscope with × 63 lens
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autophagy inhibitor chloroquine (Sigma) or mitophagy uncoupler CCCP (Sigma)
was used.
Cells were transfected using calcium phosphate precipitates as previously described.33
Tet-on p53 Saos-2 cells24 were induced with 1 μg/ml doxycycline (Sigma).
Ecotropic and amphotrophic retroviral infections with the following constructs were
performed in Saos-2, Saos-2 EcoR and MDA-MB-231 EcoR cells as previously
described:34 pWZL Hygro, LZRS-Parkin-wt (a kind gift from Stephen Tait), pWZL
DRAM-3 Hygro and pLZRS Parkin-YFP Zeo (a kind gift from Stephen Tait)
characterized in Tait et al.35 were carried out according to a previously described
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protocol.34 After infection, Saos-2 cells were selected with 100 μg/ml Hygromycin B
(Roche Diagnostics, Burgess Hill, UK) for 7 days or 200 μg/ml Zeocin (Invitrogen, Life
Technologies) for 10 days, as appropriate.
Saos-2 DRAM-3 KO cells were generated using a lentiviral CRISPR construct.36
Lentiviral infections were performed as previously described,37 and the infected cells
were selected with 1 μg/ml Puromycin (Sigma) for 5 days.
qRT-PCR. RNA was collected and purified according to the manufacturer’s
protocol of the Qiagen RNeasy Mini Kit (Qiagen, Venlo, Netherlands), including an
optional on-column DNase digestion. cDNA was produced using the DyNAmo
SYBR Green qPCR Kit (Life Technologies), and 1 μg RNA was used for the reverse
transcription. For human tissue analysis, we purchaed a TissueScan Human
Normal cDNA array from Origene (Rockville, MD, USA). qPCR was performed on a
Chromo4 RT-PCR detector (Bio-Rad, Hercules, CA, USA). Samples were measured
in triplicates, and results were normalized to 18S RNA control.
Primers used were as follows: 18S: fw: 5′-GTA ACC CGT TGA ACC CCATT-3′,
rev: 5′-CCA TCC AAT CGG TAG TAG CG-3′ DRAM-3 (Origene): fw: 5′-GTC
TGC ACC ATC CTC ATT GTG G-3′, rev: 5′-CGG AGA AGT CAA CGG CTA AGA G
-3′ DRAM-1 full length: fw: 5′-GCC ACA TAC GGA TGG TCA TCT CTG-3′, rev:
5′-GTG ACA CTC TGG AAA TCT TGG GAT-3′.
Clonogenic assays. For clonogenic assays, cells were seeded in 10 -cm
dishes or six-well plates and left attached for 24 h before treatment. For starvation
assays, cells were washed four times with PBS and incubated with starvation
media. Media was exchanged to normal growth media at the indicated time points
and cells were left growing for further 3–7 days.
Cell staining was performed using Giemsa-modified stain (Sigma). In short, cells
were washed with PBS once and then incubated with Giemsa stain for 15 min. The
stained cells were then washed with 10% methanol four times and left drying
overnight.
Western blotting. Protein extraction was performed as previously described.38
Protein lysates were separated by SDS–PAGE and blotted onto PVDF membranes.
Western blot analysis was performed according to standard techniques. Antibodies
used were as follows: α-actin (Abcam, Cambridge, UK; ab8227), α-LC3B (Cell
Signaling, Danvers, MA, USA; #2775), α-Myc-Tag (Millipore, Darmstadt, Germany;
05 – 724), α-GFP (Covance, Princeton, NJ, USA; B34), α-p53 DO1 (BD Bioscience,
Oxford, UK; #554293), α-p62 (Sigma; p0067), α-BSA (Santa Cruz, Dallas, TX,
USA; clone 25G7) and α-COX IV (Abcam; ab16056).
Confocal microscopy. For Immunofluorescence studies, cells were grown on
glass coverslips for 2 days, then the coverslips were washed once in PBS and then
fixed with 4% p-formaldehyde for 30 min at room temperature. Immunofluorescence
staining of cells was carried out as previously described.39 An Olympus FV1000
confocal microscope with a 60 × objective and a Zeiss 710 confocal microscope with
× 63 objective were used for taking images.
Antibodies used were as follows: α-Myc-Tag (Millipore; 4A6), α-Myc-Tag
(Cell Signaling; #2272), α-LC3B (Cell Signaling; #2775), α-LAMP2 (BD Pharmingen,
San Jose, CA, USA; CD107b), α-EEA1 (Abcam, ab2900), α-Calnexin (Cell Signaling;
#2679), α-WIPI2 (Bio-rad; MCA578OGA) and α-GM130 (BD Bioscience, #610822).
For live-cell imaging, cells were transfected with GFP-tagged DRAM-3 and RFP-
tagged Rab5 or Rab7 at least 2 days before confocal analysis. An Andor spinning disc
confocal system with Cairn Optsplit (for simultaneous GFP/RFP imaging) was used
for imaging. Videos of endosomes were taken for 1 min, with pictures in 1-s intervals.
Flow cytometry. Flow cytometry for unfixed (cell death assay) and methanol-
fixed (cell cycle profile assay) cells was conducted as previously described,37 and a
FACS Calibur was used for the analysis. All samples were measured in triplicates.
For Annexin V/PI analysis, cells were stained with propidium iodide and Annexin
V-Alexa 488 antibody according to the manufacturers instructions (Life
Technologies).
Genomic DNA purification and sequencing. Genomic DNA of
lentiCRISPR containing cells was isolated and purified using the Qiagen MiniAmp
DNA mini Kit. The DRAM-3 sequence targeted by the CRISPR constructs was
amplified by PCR, using 20 ng of genomic DNA of each cell line and a HotStar High
Fidelity Polymerase kit (Qiagen). PCR was performed for 40 cycles, and the PCR
products were run on a 2% agarose gel. After excision, gel purification was
performed using the Qiagen QIAquick Gel Extraction Kit and the purified product
(~500 bp) was sequenced.
PCR primers were as follows: fw: 5′-CGC TCC TTT CTC AAA CCC AG-3′; rev:
5′-GAG CAA AGG AAT CCA GCC G-3′ Sequencing primers: fw: 5′-AGG
AGT CCA TGC CCC AGG-3′; rev: 5′-TAA GCC TAT GGC CAC GGG G-3′.
Mitophagy assay. Parkin-wt or Parkin-YFP containing cells were treated once
(CRISPR cells) for 16 h or twice (Saos-2 pWZL cells) for a total of 24 h with 12.5 μM
of the mitochondrial depolarizer CCCP (Sigma). Mitochondrial content was
measured via COX IV Western blotting.
BCA uptake. To measure general endocytic uptake, cells were starved in
serum-free media for 3.5 h and then refed with 1 mg/ml BSA (BP1605-100, Thermo
Fisher Scientific, Waltham, MA, USA) and collected at different time points
post-refeeding. BSA uptake was measured via Western blot detection of BSA. Data
from 3 experiments were used to produce uptake kinetics.
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